Seeking Alpha

Seeking Alpha Portfolio App for iPad

LATEST ARTICLES

ARTICLES | NEWS | TRANSCRIPTS

A Broad Look At Teva's Pipeline
StockRiters • TEVA • Mon, May 20, 07:46 ET
Oramed Sweeps Past Worldwide Giants With The First Trial Of Orally Delivered Insulin
Sharon di Stefano • BMY, MNKD, MRK • Sun, May 19, 16:43 ET
Israel Joins Rate Cut Club, ETF Doesn't Care And Falls
Benzinga • EIS • Mon, May 13, 13:38 ET
Teva: An Ideal Long-Term Pharma Stock
Emerging Equities • TEVA • Mon, May 13, 10:42 ET
Teva's CEO Thinks China Is A 'Natural Fit'
ChinaBio Today • TEVA • Wed, May 8, 02:02 ET
Oramed Readies Oral Insulin Study In U.S.
Len Zehr • ORMP • Tue, May 7, 18:52 ET
InspireMD: Moving Foward In Cardiac Stent Innovation
Iggy Igette • NSPR • Mon, May 6, 09:42 ET
A Sweeter Deal On The Horizon For Prolor Biotech?
Stefan Bordonaro • OPK, PBTH • Wed, May 1, 17:46 ET
BioLineRx Pipeline Returns To The Winner's Circle
Len Zehr • BLRX • Wed, May 1, 08:43 ET
Teva Pharmaceuticals Is A Bitter Pill To Swallow
Ron Sommer • TEVA • Sun, Apr 28, 19:47 ET
An Undervalued Pharmaceutical Company With Remarkable Results
Steffen Jørgensen • TEVA • Tue, Apr 23, 17:35 ET
Another Israel ETF Is On The Way
Benzinga • TEVA, EIS, ISRA • Tue, Apr 9, 15:48 ET
Prolor Biotech: Unlimited Upside?
Daniel Lauchheimer • ARNA, VVUS, NVO • Tue, Apr 9, 08:36 ET
Bioassociate Initiated Coverage On RedHill Biopharma With A Buy
Bioassociate Consulting • RDHL • Mon, Apr 8, 08:18 ET
Can Teva's Short-Term Pressure Be Justified?
Nick Chiu • BIIB, MYL, NVS • Fri, Apr 5, 15:05 ET
Upcoming Trial Data May Help Salvage Bioline Rx
Brian L. Wilson • BLRX • Wed, Apr 3, 14:14 ET
Adopt Prolor's Orphan Drug And Reward Your Portfolio
Daniel Lauchheimer • PBTH • Tue, Mar 5, 02:27 ET
Bioassociate Initiated Coverage On Oramed Pharmaceuticals With A Buy
Bioassociate Consulting • ORMP • Thu, Feb 21, 08:44 ET
Teva Pharmaceuticals: Beaten, Bludgeoned And Brutalized - It's A Buy
Craig Van Pelt • TEVA • Thu, Jan 31, 11:21 ET
Teva Pharmaceuticals - Food For Thought
Yair Guterman • PFE, TEVA • Tue, Jan 15, 08:56 ET
BioLineRx: Upcoming Catalyst With Potential Multi Billion-Dollar Schizophrenia Drug
Scott Matusow • ACAD, DRRX, JNJ • Tue, Jan 15, 08:01 ET
Can Change Save Teva From Falling Off The Patent Cliff?
C.R. Jackson • TEVA • Wed, Jan 9, 18:20 ET
Teva: A 'Show Me' Stock That May Show Patient Investors Profits
Scott Tapley • TEVA • Wed, Jan 9, 17:14 ET
Is Prolor Biotech As Long Lasting As Its CTP Technology?
Benjamin Paluch • PBTH, MRK • Tue, Jan 1, 03:16 ET
Teva Pharmaceutical: A Company In Transition
Ron Sommer • TEVA • Mon, Dec 31, 2012, 06:21 ET
Teva's New Focused Corporate Strategy Is Just What The Doctor Ordered
Saibus Research • TEVA • Fri, Dec 21, 2012, 02:18 ET
Takeaways From Teva's Analyst Day: 'Restoring Shareholder Value'
Logical Assessment • PBTH, SGYP, TEVA • Thu, Dec 20, 2012, 11:25 ET
Is There Still Hope For Teva Investors?
Stock Whisper • TEVA • Wed, Dec 12, 2012, 10:17 ET
Why Teva's Shares Are Cheap, Nearly Topping Our Scale
Valuentum • TEVA • Thu, Dec 6, 2012, 15:51 ET
BioLineRx: Israeli Biotech Incubator With Multiple Near-Term Clinical Catalysts
Mike Havrilla • BLRX • Thu, Dec 6, 2012, 10:04 ET
Prolor Biotech: A Critical Year For Company With Results Expected For Lead Drug In Development
Josh Hutheson • TEVA, PBTH • Wed, Dec 5, 2012, 18:38 ET
Buying Teva's Immunotherapy Investment
James Stocklasar Thomas Jr. • TEVA, CVM • Wed, Dec 5, 2012, 15:57 ET
Teva Deserves A Better Valuation
Nick Chiu • BIIB, NVS, TEVA • Tue, Dec 4, 2012, 05:38 ET
Buy Teva And Expect A Dividend Hike On December 11th
Stock Whisper • TEVA • Mon, Dec 3, 2012, 11:19 ET
BioLine Is Approaching Its Moment Of Truth
Bioassociate Consulting • AZN, BMY, LLY • Mon, Dec 3, 2012, 06:20 ET
Teva Pharmaceuticals: 2013 Revised Guidance Could Signal A Buying Opportunity
Regarded Solutions • TEVA • Mon, Dec 3, 2012, 04:53 ET
TEVA: Lower Expectations Out Of The Way, Stock Should Climb Into Investor Day
PropThink • TEVA • Fri, Nov 30, 2012, 10:45 ET
Teva: What Would Be The Best Acquisition Candidate?
Jorge Aura • CLSN, ZLCS, TEVA • Wed, Nov 28, 2012, 15:38 ET
Revisiting Buyout Rumors After Teva's CEO Shifts Focus To 'Smaller Acquisitions'
Logical Assessment • BMY, LLY, NVS • Wed, Nov 21, 2012, 10:23 ET
Teva Is Still Healthier Than Its Big Pharma Peers
Saibus Research • AZN, BMY, GSK • Wed, Nov 14, 2012, 14:00 ET
Teva: Rumors Of Copaxone's Demise Have Been Greatly Exaggerated
Saibus Research • BIIB, BMY, NVO • Tue, Nov 6, 2012, 16:54 ET
3 Solid Healthcare Stocks To Ride The Baby Boomer Trend Through Options
Nick Chiu • JNJ, NVS, TEVA • Tue, Nov 6, 2012, 13:58 ET
Teva Pharmaceutical - A Fundamentals-Driven Dividend Growth Stock Value Idea For November 5
F.A.S.T. Graphs • TEVA • Mon, Nov 5, 2012, 10:48 ET
Teva Pharmaceuticals: Valuation Is Too Depressed On Worries About Copaxone
The Value Investor • TEVA • Mon, Nov 5, 2012, 05:22 ET
New CEO Will Cure Teva's Ailments
Saibus Research • TEVA • Fri, Nov 2, 2012, 04:19 ET
Teva: Copaxone And Management Uncertainty May Be Hiding One Of The Last Bargains Around
Gabriele Grego • TEVA • Wed, Oct 31, 2012, 09:33 ET
Drug Shortage, Aging Baby Boomers Create A Great Opportunity For Teva
Nick Chiu • TEVA • Sat, Oct 27, 2012, 12:26 ET
Prolor Biotech To Benefit From 'Bio-Better' Drug As Novo Nordisk Pulls Out
Nouvelle Asset Management • PBTH, NVO, PFE • Mon, Oct 22, 2012, 17:29 ET
A New And Interesting Addition To The Hep C Clinical Pipeline
Leonard O'Brien • BLRX • Wed, Oct 17, 2012, 12:30 ET
iShares Israel ETF's Amazingly Low P/E Ratio
Street One Financial • EIS • Tue, Oct 16, 2012, 16:26 ET

First Page
Previous Page
1 - 50 of 208
Next Page
Last Page